An update on palonosetron hydrochloride for the treatment of radio/chemotherapy-induced nausea and vomiting

Bibliography

• Navari RM. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting- two new agents. J Support Oncol 2003;1(2):89-103
   PubMedGoogle Scholar
• Edwards CM. Chemotherapy induced emesis-mechanisms and treatment: a review. J Royal Soc Med 1988;81:658-62
   PubMedGoogle Scholar
• Grunberg SM, Deuson RR, Mavros P, Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer 2004;100(10):2261-8
   PubMed Web of Science ®Google Scholar
• Pradermdee P, Manusirivithaya S, Tangjitgamol S, Antiemetic effect of ondansetron and dexamethasone in gynecologic malignant patients receiving chemotherapy. J Med Assoc Thai 2006;89(Suppl 4):S29-36
   PubMedGoogle Scholar
• Aapro M, Johnson J. Chemotherapy-induced emesis in elderly cancer patients: the role of 5-HT3-receptor antagonists in the first 24 hours. Gerontology 2005;51:287-96
   PubMedGoogle Scholar
• Massa E, Astara G, Madeddu C, Palonosetron plus dexamethasone effectively prevents acute and delayed chemotherapy-induced nausea and vomiting following highly or moderately emetogenic chemotherapy in pre-treated patients who have failed to respond to a previous antiemetic treatment: comparison between elderly and non-elderly patient response. Crit Rev Oncol Hematol 2009;70:83-91
   PubMedGoogle Scholar
• Gridelli C, Aapro M. Factors influencing the choice of 5-HT3-receptor antagonist antiemetics: focus on elderly cancer patients. Support Care Cancer 2004;12:487-96
   PubMed Web of Science ®Google Scholar
• Hesketh PJ. Chemotherapy induced nausea and vomiting. N Eng J Med 2008;358(23):2482-94
   PubMed Web of Science ®Google Scholar
• Aloxi® (palonosetron HCl) prescribing information. 2003/2005. Bloomington, MN, USA: MGI Pharma, Inc.: (2003). Helsinn Birex Pharmaceuticals Ltd; Damastown, Dublin, Republic of Ireland;2005
   Google Scholar
• Wong EH, Clark R, Leung E, The interaction of RS 25259-197, a potent and selective antagonist, with 5-HT3 receptors, in vitro. Br J Pharmacol 1995;114(4):851-9
   PubMed Web of Science ®Google Scholar
• Eglen RM, Lee C-H, Smith WL, Pharmacological characterization of RS 25259 197, a novel and selective 5-HT3 receptor antagonist, in vivo. Br J Pharmacol 1995;114:860-6
   PubMed Web of Science ®Google Scholar
• Thompson AJ, Lummis SC. The 5-HT3 receptor as a therapeutic target. Expert Opin Ther Targets 2007;11(4):527-40
   PubMed Web of Science ®Google Scholar
• Hesketh PJ, Van Belle S, Aapro M, Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists. Eur J Cancer 2003;39:1074-80
   PubMed Web of Science ®Google Scholar
• Anzemet (dolasetron mesylate injection) prescribing information. Aventis Pharmaceuticals Inc; Kansas City, MO; 2003
   Google Scholar
• MGI Pharma. Aloxi (palonosetron HCl injection) [package insert]. MGI Pharma; Bloomington, MN; 2004
   Google Scholar
• Micromedex drug information database. Thomson Healthcare; Greenwood Village, CO; 2006
   Google Scholar
• Gralla R, Lichinitser M, Van Der Vegt S, Palonosetron improves prevention of chemotherapy induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 2003;14(10):1570-7
   PubMed Web of Science ®Google Scholar
• Eisenberg P, Figueroa-Vadillo J, Zamora R, 99-04 Palonosetron Study Group Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer 2003;98(11):2473-82
   PubMed Web of Science ®Google Scholar
• Aapro MS, Grunberg SM, Manikhas GM, A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 2006;17:1441-9
   PubMed Web of Science ®Google Scholar
• Aapro MS, Bertoli L, Lordic F, Palonosetron is effective in preventing acute and delayed chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy [abstract A-17] Support Care Cancer. 2003;11(6):391
   Google Scholar
• Stoltz R, Parisi S, Shah A, Macciocchi A. Pharmacokinetics, metabolism and excretion of intravenous [l4C]-palonosetron in healthy human volunteers. Biopharm Drug Dispos 2004;25(8):329-37
   PubMed Web of Science ®Google Scholar
• Geling O, Eichler HG. Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol 2005;23:1289-94
   PubMed Web of Science ®Google Scholar
• Rojas C, Thomas AG, Alt J, Palonosetron triggers 5-HT(3) receptor internalization and causes prolonged inhibition of receptor function. Eur J Pharmacol 2010;626(2-3):193-9
   PubMed Web of Science ®Google Scholar
• Decker GM, DeMeyer ES, Kisko DL. Measuring the maintenance of daily life activities using the functional living index-emesis (FLIE) in patients receiving moderately emetogenic chemotherapy. J Support Oncol 2006;4:35-41, 52
   PubMedGoogle Scholar
• Einhorn LH, Brames MJ, Dreicer R, Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer. Support Care Cancer 2007;15(11):1293-300
   PubMedGoogle Scholar
• Giralt SA, Mangan KF, Maziarz RT, Three palonosetron regimens to prevent CINV in myeloma patients receiving multiple-day high-dose melphalan and hematopoietic stem cell transplantation. Ann Oncol 2011;22(4):939-46
   PubMed Web of Science ®Google Scholar
• Gebbia V, Cannata G, Testa A, Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting. Results of a prospective randomized trial. Cancer 1994;74(7):1945-52
   PubMed Web of Science ®Google Scholar
• Saito M, Aogi K, Sekine I, Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol 2009;10(2):115-24
   PubMed Web of Science ®Google Scholar
• Likun Z, Xiang J, Yi B, A systematic review and meta-analysis of intravenous palonosetron in the prevention of chemotherapy-induced nausea and vomiting in adults. Oncologist 2011;16(2):207-16
   PubMedGoogle Scholar
• Hajdenberg J, Grote T, Yee L, Infusion of palonosetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomiting. J Support Oncol 2006;4(9):467-71
   PubMedGoogle Scholar
• Decker GM, DeMeyer ES, Kisko DL. Measuring the maintenance of daily life activities using the Functional Living Index-Emesis (FLIE) in patients receiving moderately emetogenic chemotherapy. J Support Oncol 2006;4:35-41
   PubMedGoogle Scholar
• Celio L, Frustaci S, Denaro A, Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multi center, phase III trial. Support Care Cancer 2011;19:1217-25
   PubMed Web of Science ®Google Scholar
• Celio L, Bonizzoni E, Bajetta E, Palonosetron plus single-dose dexamethasone for the prevention of nausea and vomiting in women receiving anthracycline/cyclophosphamide-containing chemotherapy: meta-analysis of individual patient data examining the effect of age on outcome in two phase III trials. Eur J Cancer 2011;47(Suppl 2):239
   PubMedGoogle Scholar
• Aapro M, Fabi A, Nole F, Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. Ann Oncol 2010;21:1083-8
   PubMed Web of Science ®Google Scholar
• Roscoe JA, Heckler CE, Morrow GR, Prevention of delayed nausea: a University of Rochester Cancer Center Community Clinical Oncology Program study of patients receiving chemotherapy. J Clin Oncol 2012;30(27):3389-95
   PubMedGoogle Scholar
• Kris MG. Why do we need another antiemetic? Just ask. J Clin Oncol 2003;21:4077-80
   PubMed Web of Science ®Google Scholar
• Diemunsch P, Grelot L. Potential of substance P antagonists as antiemetics. Drugs 2000;60:533-46
   PubMed Web of Science ®Google Scholar
• Warr DG, Hesketh PJ, Gralla RJ, Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 2005;23:2822-30
   PubMed Web of Science ®Google Scholar
• Hesketh PJ, Grunberg SM, Gralla RJ, The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin-the Aprepitant Protocol 052 Study Group. J Clin Oncol 2003;21:4112-19
   PubMed Web of Science ®Google Scholar
• Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 2003;97:3090-8
   PubMed Web of Science ®Google Scholar
• De Wit R, Herrstedt J, Rapoport BL, Addition of the oral NK1 antagonist aprepitant to standard antiemetics provided protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. J Clin Oncol 2003;21:4105-11
   PubMed Web of Science ®Google Scholar
• Herrstedt J, Muss HB, Warr DG, Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy. Cancer 2005;104:1548-55
   PubMed Web of Science ®Google Scholar
• De Wit R, Herrstedt J, Rapoport B, The oral NK1 antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III trials. Eur J Cancer 2004;40:403-10
   PubMed Web of Science ®Google Scholar
• Navari R, Reinhardt R, Gralla RJ, Reduction of cisplatin- induced emesis by a selective neurokinin-1 receptor antagonist. N Engl J Med 1999;340:190-5
   PubMed Web of Science ®Google Scholar
• Van Belle S, Lichinitser MR, Navari R, Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869: a randomized controlled trial. Cancer 2002;94:3032-41
   PubMed Web of Science ®Google Scholar
• Campos D, Pereira JR, Reinhardt RR, Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. J Clin Oncol 2001;19:1759-67
   PubMed Web of Science ®Google Scholar
• Albany C, Brames MJ, Fausel C, Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimens: a Hoosier Oncology Group study. J Clin Oncol 2012;30:3998-4003
   PubMed Web of Science ®Google Scholar
• Basch E, Prestrud AA, Hesketh PJ, Antiemetics: American Society of Clinical Oncology clinical practice guidelines update. J Clin Oncol 2011;29:4189-
   PubMed Web of Science ®Google Scholar
• Roila F, Herrstedt J, Aapro M, Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the perugia multinational consensus conference. Ann Oncol 2010;21(Suppl 5):228-39
   Google Scholar
• Roila F, Hesketh PJ, Herrstedt J. Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer. Prevention of chemotherapy- and radiotherapy induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol 2006;17:20-8
   PubMed Web of Science ®Google Scholar
• Grunberg SM, Dugan M, Muss H, Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy. Support Care Cancer 2009;17:589-94
   PubMed Web of Science ®Google Scholar
• Hesketh PJ, Sanz-Altamira P. Aprepitant, dexamethasone, and palonosetron in the prevention of doxorubicin/cyclophosphamide-induced nausea and vomiting. Support Care Cancer 2012;20:653-6
   PubMed Web of Science ®Google Scholar
• Grote T, Hajdenberg J, Cartmell A, Combination therapy for chemotherapy induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant. J Support Oncol 2006;4:403-8
   PubMedGoogle Scholar
• Longo F, Mansueto G, Lapadula V, Palonosetron plus 3-day aprepitant and dexamethasone to prevent nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer 2011;19(8):1159-64
   PubMed Web of Science ®Google Scholar
• Gao H, Liang Y, Zhou N, Aprepitant plus palonosetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin-based chemotherapy. Int Med J 2013;43:73-6
   Google Scholar
• National Comprehensive Cancer Network: clinical practice guidelines in oncology: antiemesis, version 1. 2012. Available from: http://www.nccn.org/professionals/physician gls/PDF/antiemesis.pdf [Accessed September 27, 2011]
   Google Scholar
• Dennis K, Maranzano E, De Angelis C, Radiotherapy-induced nausea and vomiting. Expert Rev Pharmacoecon Outcomes Res 2011;685-92
   PubMedGoogle Scholar
• Feyer PC, Maranzano E, Molassiotis A, Radiotherapy-induced nausea and vomiting (RINV): MASCC/ESMO guideline for antiemetics in radiotherapy: update 2009. Support Care Cancer 2011;19(Suppl 1):5-14
   PubMed Web of Science ®Google Scholar
• Maranzano E, De Angelis V, Pergolizzi S, A prospective observational trial on emesis in radiotherapy: analysis of 1020 patients recruited in 45 Italian radiation oncology centres. Italian Group for Antiemetic Research in Radiotherapy - IGARR. Radiother Oncol 2010;94:36-41
   PubMed Web of Science ®Google Scholar
• Dennis K, Zhang L, Lutz S, International patterns of practice in the management of radiation therapy-induced nausea and vomiting. Int J Radiat Oncol Biol Phys 2012;
   Google Scholar
• De Moor C, Cohen P, Eisenberg PD, Oncologists compliance with anti-emetic guidelines and outcomes of patients receiving emetogenic chemotherapy. Proc Am Soc Clin Oncol 2003;22:727
   Google Scholar
• de Moor C, Cunningham RS. Improving the functional status of patients with cancer by more effectively preventing chemotherapy induced nausea and vomiting (CINV): a comparison of palonosetron (PALO) vs ondansetron (OND) or dolasetron (DOL). J Support Oncol 2005;3(5 Suppl 3):25-6; PA–12
   Google Scholar
• Eisenberg P, MacKintosh FR, Ritch P, Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: a dose ranging clinical study. Ann Oncol 2004;15:330-7
   PubMed Web of Science ®Google Scholar
• Grunberg S, Vanden Burgt J, Berry S, Prevention of delayed nausea and vomiting (D-CINV): carryover effect analysis of pooled data from 2 phase III studies of palonosetron (PALO). J Clin Oncol 2004;22:A8051
   Web of Science ®Google Scholar
• Grunberg SM, Deuson RR, Mavros P, Incidence of chemotherapy induced nausea and emesis after modern antiemetics. Cancer 2004;100:2261-8
   PubMed Web of Science ®Google Scholar
• Grunberg SM, Koeller JM. Palonosetron: a unique 5-HT3-receptor antagonist for the prevention of chemotherapy-induced emesis. Expert Opin Pharmacother 2003;4:2297-303
   PubMed Web of Science ®Google Scholar
• Rubenstein EB, Gralla RJ, Eisenberg P, Palonosetron (PALO) compared with ondansetron (OND) or dolasetron (DOL) for prevention of acute and delayed chemotherapy induced nausea and vomiting (CINV): combined results of two phase III trials. Proc Am Soc Clin Oncol 2003;22:729; A2932
   Web of Science ®Google Scholar
• Celio L, Denaro A, Canova S, Clinical update on palonosetron in the management of chemotherapy-induced nausea and vomiting. Tumori 2008;94:447-52
   PubMedGoogle Scholar
• Voisin D, Grunberg S. Efficacy of oral palonosetron compared to intravenous palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: a phase 3 trial. ESMO 2012
   Google Scholar
• Ikari Y, Nakasima Y, Sato E, Safety and pharmacokinetic evaluation of palonosetron given on day 1 and 3 for patients who are to receive a high or moderate risk of chemotherapy-induced nausea and vomiting (CINV) [abstr. 1576p |]. ESMO 2012
   Google Scholar